Study S002806

The Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of Continuous Multiple Dose PB-119 Injection in Health Volunteers

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03062774
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 36
Start: 2014-11-15
Primary completion: 2016-09-13
Lead sponsor: PegBio Co., Ltd.
Conditions: Type2 Diabetes Mellitus
Interventions: BIOLOGICAL:PB-119 injection
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [Change from Baseline lab value at 50 days]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023592	Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. Cui H, European journal of drug metabolism and pharmacokinetics	2021	Other trial	PMID 33576936 DOI	cites ClinicalTrials.gov:NCT03062774; registry reference DERIVED:33576936